Condition
Stage IV Uveal Melanoma
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
133%
4 of 3 completed with results
Key Signals
4 with results75% success
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01473004Phase 2CompletedPrimary
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
NCT02359851Phase 2Terminated
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
NCT01961115Phase 2Completed
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT01143402Phase 2Completed
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Showing all 4 trials